A Real-World Experience of Hyperkalemia Management Using Sodium Zirconium Cyclosilicate in Chronic Hemodialysis: A Multicenter Clinical Audit.

Abstract

Hyperkalemia, a common condition among hemodialysis (HD) patients, is associated with adverse health outcomes.Evidence of the safety and efficacy of a potassium-binder, sodium zirconium cyclosilicate (SZC), has been limited among Asian(HD) patients beyond phase 3 trials.This article demonstrates real-world evidence of SZC usage in an Asian cohort of HD patients. A retrospective clinical audit was conducted among 293 patients who received maintenance HD at community-based dialysis centers in Singapore.Patients received SZC for either management of hyperkalemia or hyperkalemia prevention during anticipated disruption to dialysis, such as during traveling.Among patients treated for hyperkalemia (N = 147), serum potassium (K+) prior to SZC initiation and at the endpoint was compared using a paired Student's t-test.Changes in K+ from baseline to endpoint were compared across various categories within each demographic and health-related variables using either Student's t-test or one-way ANOVA.Patients who experienced adverse events after SZC initiation or were deceased during the audit were reviewed to provide a descriptive account. Among patients who received SZC for hyperkalemia treatment, SZC use was associated with a significant reduction of 0.812 mmol/L in serum potassium.Patients with ethnicities other than Chinese, Malay, or Indianhad a nominal reduction in K+ of 0.7 mmol/L and this can be accounted for the small sample size of this sub-group.The three main ethnicities which represented more than 95% of the sampleshowed a significant reduction in K+ levels(all three p<0.001).This is consistent with other studies with SZC which showedefficacy across various ethnicities.Patients who received SZC for hyperkalemia treatment or prevention had a significant lowering of mortality rate.This mortality reduction may have inherent biases and confounders, due to the retrospective clinical audit study design. Conclusions:Overall, SZC was safe and effective among the audited patients.The efficacy in the real-world setting was similar to previous trials.The novel use of SZC to manage serum potassium when HD sessions are missed, such as during traveling, warrants further investigation due to potentially significant life-saving implications.